Please login to the form below

Not currently logged in
Email:
Password:

David Barratt launches new consultancy

Former CEO of Euro RSCG Life, David Barratt, has launched Healthcare Communications Consultancy (HCC), a specialist management consultancy

Former CEO of Euro RSCG Life, David Barratt, has launched Healthcare Communications Consultancy (HCC), a specialist management consultancy serving both network and independent agencies and working with procurement departments within global pharmaceutical companies.

In late 2007, Barratt took-over the helm at Euro RSCG Life.  Fifteen months later, he set up a second agency, Health 4 Brands. Following a reorganisation in mid-2010, Barratt moved on to set-up his own company.

"The demands on agency leaders have increased dramatically over the last five years. As a result, running accounts and managing stretched teams plus continually having to fire fight, means that heads of agencies often do not have enough time to do the important strategic thinking and general management that is necessary. As someone who has set up two agencies and successfully turned around two others, I can best use my experience to help a wide variety of companies offering advertising, design, med comms/ed, PR and digital services. I get huge satisfaction from helping agencies to develop and grow," said Barratt.

Prior to Euro RSCG Life, Barratt was MD of Lowe Azure and Lowe Fusion, and MD of ApotheCom Europe. He also ran his own agency for 14 years.

2nd March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...